Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Down 5.69%
As of Friday, August 28, Polaryx Therapeutics, Inc.’s PLYX share price has dipped by 5.69%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Commentary & Analysis
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 8.12%
As of Tuesday, August 25, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 8.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Down 7.30%
As of Monday, August 17, Polaryx Therapeutics, Inc.’s PLYX share price has dipped by 7.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 5.38%
As of Thursday, August 13, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 5.38%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Polaryx Therapeutics, Inc.’s (PLYX) Stock Is Up 11.21%
As of Thursday, August 13, Polaryx Therapeutics, Inc.’s PLYX share price has surged by 11.21%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $106.7 | $559.4 | 22% |
|
| Shares Out (Mil) | 48.3 | 42.7 | 46% |
|
| Institutional Ownership | 12.8% | 84.1% | 7% |
|
| Float (Mil) | 6.8 | 45.1 | 15% |
|
| Beta | na | 0.72 | na |
|
| Avg Daily Volume (000s) | 33 | 431 | 24% |
|
| Price Change (52-week) |
na | 62.3% | na |
|
| Growth | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | (1.4%) | na |
|
| EPS (5yr) | na | 15.1% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.0%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($7) | ($11) | 32% |
|
| EPS (TTM) | ($0.146) | ($0.600) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($6) | ($6) | 24% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $96 | $493 | 21% |
|
| Valuation | PLYX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.73 | 2.42 | 90% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PLYX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (89.2%) | (22.0%) | 6% |
|
| ROE | (96.6%) | (21.8%) | 9% |
|
| Liabilities to Assets | 7.4% | 32.6% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
Polaryx Therapeutics, Inc. did not pass any screens on 9/24/2026.
